High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.
Tang Y, Yin H, Zhao X, Jin D, Liang Y, Xiong T, Li L, Tang W, Zhang J, Liu M, Yu Z, Liu H, Zang S, Huang Z.
Tang Y, et al.
J Exp Clin Cancer Res. 2022 Jan 3;41(1):2. doi: 10.1186/s13046-021-02214-z.
J Exp Clin Cancer Res. 2022.
PMID: 34980210
Free PMC article.